Akèy › Glomeruloskleroz fokal segmantè
Etid klinik pou Glomeruloskleroz fokal segmantè ap rekrite nan Etazini
17 etid pou Glomeruloskleroz fokal segmantè ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Philadelphia, PA9 etid
- Durham, NC8 etid
- New York City, NY7 etid
- Los Angeles, CA6 etid
- Miami, FL6 etid
- Queens, NY6 etid
- Ann Arbor, MI6 etid
- Atlanta, GA5 etid
- Houston, TX5 etid
- Kansas City, MO4 etid
- Cleveland, OH4 etid
- Chicago, IL4 etid
- Dallas, TX4 etid
- Minneapolis, MN3 etid
- Charleston, SC3 etid
- Orlando, FL3 etid
- Seattle, WA3 etid
- Columbus, OH3 etid
- Baltimore, MD3 etid
- Kansas City, KS3 etid
- San Francisco, CA3 etid
Pa eta
- Colorado4 etid
- Delaware3 etid
- Florid7 etid
- Georgia6 etid
- Illinois4 etid
- Kalifòni8 etid
- Kansas3 etid
- Maryland4 etid
- Michigan10 etid
- Minnesota5 etid
- Missouri5 etid
- New York11 etid
- North Carolina9 etid
- Ohio8 etid
- Pennsylvania9 etid
- South Carolina6 etid
- Texas5 etid
- Washington3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07220083An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
Ap rekriteFaz 2
Laj 18 a 115 · Tout sèks · Mizajou Sep 30, 2026 · NCT06664814A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Ap rekriteFaz 2
Laj 16 a 75 · Tout sèks · Mizajou Sep 23, 2026 · NCT06500702Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
Ap rekrite
Jiska laj 21 · Tout sèks · Mizajou Aug 28, 2026 · NCT02235857Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
Ap rekrite
Jiska laj 75 · Tout sèks · Mizajou Aug 28, 2026 · NCT04065438A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 13, 2026 · NCT07268638NEPTUNE Match Study
Ap rekrite
Laj 1 a 80 · Tout sèks · Mizajou Jun 10, 2026 · NCT04571658Nephrotic Syndrome Study Network
Ap rekriteEtid obsèvasyon
Jiska laj 80 · Tout sèks · Mizajou Jun 10, 2026 · NCT01209000Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Ap rekriteFaz 2
Laj 1 a 17 · Tout sèks · Mizajou May 12, 2026 · NCT05003986Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Apr 29, 2026 · NCT05650619A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
Ap rekrite
Laj 3 a 17 · Tout sèks · Mizajou Apr 17, 2026 · NCT05583942taVNS for FRNS in Children
Ap rekrite
Laj 3 a 17 · Tout sèks · Mizajou Apr 15, 2026 · NCT05588063SLIT ABS: Study on Patients With Autoimmune Podocytopathy
Ap rekrite
Laj 0 a 99 · Tout sèks · Mizajou Apr 8, 2026 · NCT07516964AMPK-activation by Metformin in FSGS: AMP-FSGS
Ap rekriteFaz 1/2
Laj 18 a 80 · Tout sèks · Mizajou Feb 3, 2026 · NCT06090227A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Ap rekriteFaz 3
Laj 12 a 80 · Tout sèks · Mizajou Feb 3, 2026 · NCT05183646Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
Ap rekriteEtid obsèvasyon
Laj 2 ak plis · Tout sèks · Mizajou Dec 22, 2025 · NCT05505500Proteinuria in Pre and Post Transplant
Ap rekriteEtid obsèvasyon
Jiska laj 25 · Tout sèks · Mizajou Nov 21, 2025 · NCT01094327Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.